GeneThera Inc
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacte… Read more
GeneThera Inc (GTHR) - Net Assets
Latest net assets as of December 2022: $-8.17 Million USD
Based on the latest financial reports, GeneThera Inc (GTHR) has net assets worth $-8.17 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.30K) and total liabilities ($8.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.17 Million |
| % of Total Assets | -129684.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 87.6 |
GeneThera Inc - Net Assets Trend (1997–2022)
This chart illustrates how GeneThera Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeneThera Inc (1997–2022)
The table below shows the annual net assets of GeneThera Inc from 1997 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-8.17 Million | 0.00% |
| 2021-12-31 | $-8.17 Million | -6.41% |
| 2020-12-31 | $-7.68 Million | -10.97% |
| 2019-12-31 | $-6.92 Million | +3.70% |
| 2018-12-31 | $-7.19 Million | 0.00% |
| 2017-12-31 | $-7.19 Million | -0.92% |
| 2016-12-31 | $-7.12 Million | -9.16% |
| 2015-12-31 | $-6.52 Million | -13.68% |
| 2014-12-31 | $-5.74 Million | -8.64% |
| 2013-12-31 | $-5.28 Million | -15.72% |
| 2012-12-31 | $-4.56 Million | -51.25% |
| 2011-12-31 | $-3.02 Million | -31.58% |
| 2008-12-31 | $-2.29 Million | -71.49% |
| 2007-12-31 | $-1.34 Million | -30.65% |
| 2006-12-31 | $-1.02 Million | -138.69% |
| 2005-12-31 | $-428.92K | -134.52% |
| 2004-12-31 | $-182.89K | +62.94% |
| 2003-12-31 | $-493.52K | +33.35% |
| 2002-12-31 | $-740.45K | -545.82% |
| 2001-12-31 | $-114.65K | -169.96% |
| 2000-12-31 | $163.90K | -38.48% |
| 1999-12-31 | $266.43K | +77.21% |
| 1998-12-31 | $150.34K | -31.66% |
| 1997-12-31 | $220.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneThera Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3216144600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $34.08K | % |
| Other Comprehensive Income | $53.57K | % |
| Other Components | $24.01 Million | % |
| Total Equity | $-8.17 Million | 100.00% |
GeneThera Inc Competitors by Market Cap
The table below lists competitors of GeneThera Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Faysal Bank Ltd
KAR:FABL
|
$2.92K |
|
Sweden BuyersClub AB
ST:BUY
|
$2.92K |
|
Millerful No. 1 REIT
TW:01010T
|
$2.93K |
|
Clone Algo Technologies Inc
PINK:CATI
|
$2.93K |
|
Ondo InsurTech PLC
LSE:ONDO
|
$2.92K |
|
Auxilia SA
WAR:AUX
|
$2.91K |
|
ANGES MG
MU:AJW
|
$2.91K |
|
China Changjiang Mining & New Energy Co Ltd
PINK:CHJI
|
$2.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneThera Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -8,172,688 to -8,172,688, a change of 0.
- Net loss of 1,011,485 reduced equity.
- Other factors increased equity by 1,011,485.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.01 Million | -12.38% |
| Other Changes | $1.01 Million | +12.38% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares GeneThera Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | $0.01 | $0.00 | x |
| 1998-12-31 | $603.79 | $0.00 | x |
| 1999-12-31 | $1069.98 | $0.00 | x |
| 2000-12-31 | $-104.84 | $0.00 | x |
| 2001-12-31 | $-824.85 | $0.00 | x |
| 2002-12-31 | $-1591.05 | $0.00 | x |
| 2003-12-31 | $-140.05 | $0.00 | x |
| 2004-12-31 | $-47.67 | $0.00 | x |
| 2005-12-31 | $-102.25 | $0.00 | x |
| 2006-12-31 | $-223.34 | $0.00 | x |
| 2007-12-31 | $-132.50 | $0.00 | x |
| 2008-12-31 | $-4.82 | $0.00 | x |
| 2011-12-31 | $-0.12 | $0.00 | x |
| 2012-12-31 | $-0.18 | $0.00 | x |
| 2013-12-31 | $-0.18 | $0.00 | x |
| 2014-12-31 | $-0.17 | $0.00 | x |
| 2015-12-31 | $-0.18 | $0.00 | x |
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $-0.18 | $0.00 | x |
| 2018-12-31 | $-0.18 | $0.00 | x |
| 2019-12-31 | $-0.19 | $0.00 | x |
| 2020-12-31 | $-0.38 | $0.00 | x |
| 2021-12-31 | $-0.32 | $0.00 | x |
| 2022-12-31 | $-0.32 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneThera Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-8.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -27.27% | -15.79% | 0.57x | 3.05x | $-82.00K |
| 1998 | -71.88% | -34.73% | 0.51x | 4.07x | $-123.10K |
| 1999 | -95.96% | -83.13% | 0.60x | 1.93x | $-282.31K |
| 2000 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.21K |
| 2001 | 0.00% | -304.06% | 1.15x | 0.00x | $-330.67K |
| 2002 | 0.00% | -1564.05% | 0.25x | 0.00x | $-1.20 Million |
| 2003 | 0.00% | -2533084.38% | 0.00x | 0.00x | $-2.38 Million |
| 2004 | 0.00% | -22575.13% | 0.03x | 0.00x | $-5.74 Million |
| 2005 | 0.00% | -1908.99% | 0.45x | 0.00x | $-3.60 Million |
| 2006 | 0.00% | -988.38% | 0.38x | 0.00x | $-1.38 Million |
| 2007 | 0.00% | -859.89% | 0.27x | 0.00x | $-708.07K |
| 2008 | 0.00% | -18376.52% | 0.05x | 0.00x | $-1.76 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-797.27K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.34 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-528.61K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $27.81K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-433.07K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-66.78K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.00K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-60.20K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $174.45K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.41K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-196.44K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-194.22K |
Industry Comparison
This section compares GeneThera Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneThera Inc (GTHR) | $-8.17 Million | -27.27% | N/A | $2.92K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |